Subscribe to RSS
DOI: 10.1055/s-0039-3399958
Anti-inflammatory and barrier stabilising effects of myrrh, coffee charcoal and chamomile flower extract in a multicomponent-cell-model of the intestinal mucosa
Publication History
Publication Date:
20 December 2019 (online)
The combination of myrrh (Commiphora molmol E.), coffee charcoal (Coffea Arabica L.) and chamomile flower dry extract (Matricaria chamomilla L.), known as Myrrhinil-Intest® has a long tradition in the treatment of gastrointestinal disorders in Germany. Recent clinical evidence suggests its efficacy in the therapy of inflammatory bowel diseases (IBD)[ [ 1 ] ]. However, the mechanisms of action remain to be fully elucidated.
The present study aimed to evaluate the effects of myrrh, coffee charcoal and chamomile flower extract on pro-inflammatory communication between immune and epithelial cells and the resulting barrier dysfunction. A complex co-culture-cell-model allowed the simultaneous investigation of these two IBD-characteristics.
To model the intestinal mucosa a monolayer of 90 % Caco-2 and 10 % HT29-MTX cells was differentiated on transwell-inserts for 21 days. Co-cultivation with LPS-activated THP-1 macrophages over 48 h served as inflammatory stimulus. Concomitantly the cells were treated with various concentrations of plant extracts. Cytokine (IL6, TNF) and chemokine (IL8, MCP-1) release into the supernatant were quantified by ELISA. The transepithelial electrical resistance (TEER) was measured to evaluate effects on the barrier function.
Myrrh, coffee charcoal and chamomile flower showed concentration-dependant effects on the release of pro-inflammatory mediators to varying extent. In addition a TEER-increase of inflamed monolayers could be observed with higher concentrations of myrrh and coffee charcoal. The respective IC50 and EC50 values are presented in table 1.
All three plant extracts exhibited anti-inflammatory properties. A barrier stabilising effect could be shown for myrrh and coffee charcoal. In both fields myrrh displayed the most distinct pharmacological activity.